Abstract
Background: Dupilumab is a monoclonal antibody used for the treatment of moderate/severe atopic dermatitis (AD). In recent years, several studies have confirmed the positive association between AD and overweight/obesity, and a report demonstrated the effect of weight reduction on the improvement of AD symptoms. Methods: The weight of 170 patients under treatment with dupilumab was recorded at baseline and after 48 weeks (T48). Clinical monitoring was mainly conducted using the Eczema Area and Severity Index (EASI). The study aimed to assess a possible correlation between the clinical outcome of dupilumab therapy and BMI. Results: Although not statistically significant, patients with a BMI < 25 have a higher EASI percentage improvement than patients with a BMI ≥ 25 at any time point, and the percentage of overweight and obese patients that does not reach EASI-75 at T48 is higher compared to normal-weight patients (13.5% vs. 5.9%). Despite this, in the multivariate regression analysis, no baseline characteristic, including BMI, appears to increase the risk of not reaching EASI-75. In addition, the results show no differences in BMI between baseline and T48 in any age/sex group. Conclusions: The results suggest that overweight and obese patients have a lower response to dupilumab when considering the EASI score, but this difference does not appear to be clinically significant. Furthermore, dupilumab treatment does not seem to impact weight.
Keywords: atopic dermatitis, biological therapy, body mass index (BMI), dupilumab, weight
1. Introduction
Atopic dermatitis (AD) is one of the most common chronic illnesses worldwide, affecting 3.5% of the global population (230 million people). Although it can manifest at any age [1], its incidence is highest in infancy, with around 80% of cases appearing before the age of 6 [2,3]. Clinically, AD is characterized by eczematous lesions that vary with age, yet it is also highly heterogeneous in terms of severity, progression, and sometimes specific clinical features [4]. A meta-analysis of seven birth cohort studies with follow-ups of up to 26 years suggests that the annual prevalence of AD in adults in developed countries can reach as high as 14.6%, confirming that AD is a lifelong condition [5]. A systematic review of 378 studies published globally from 1958 to 2018 found that the overall prevalence of AD in children is between 0.96% and 22.6%, while the overall prevalence of AD in adults is between 1.2% and 17.1% [6].
Interleukin (IL)-13 and IL-4 are crucial contributors to the inflammation in AD, resulting in chronic type-2 inflammation. Dupilumab is a humanized IgG4 monoclonal antibody that targets the IL-4 receptor alpha chain (IL-4Rα), which is present in both type 1 (IL-4 specific) and type 2 (IL-4 and IL-13 specific) IL-4 receptor complexes, thus inhibiting both IL-4 and IL-13 signaling. Dupilumab was the first biological therapy approved for the treatment of atopic dermatitis. Its efficacy has been proven in both clinical trials and real-life studies [7,8,9,10,11,12,13,14,15,16].
To the best of our knowledge, only a single Swedish study described a possible association between weight gain and dupilumab: in a cohort of 12 AD patients treated with dupilumab, all patients experienced significant weight gain after 48 weeks of follow-up [17]. The authors speculated that since IL-4α receptor signaling is essential for the development of postnatal brown fat, inhibiting IL-4 and IL-13 might interfere with its activation, potentially raising the risk of obesity in AD patients.
Overweight and obesity are defined by a body mass index (BMI) of 25 to 29.9 kg/m2 and a BMI of ≥30 kg/m2, respectively. In recent years, several studies have confirmed a positive association between AD and overweight/obesity in both infancy and adulthood [18,19]. Additionally, a report showed that weight reduction positively impacts the improvement of AD symptoms. [20]. The link between inflammatory dermatosis and obesity can be attributed to the fact that adipose tissue in obese individuals induces a systemic inflammatory state, resulting in altered serum levels of cytokines, chemokines, and adipokines. In particular, the level of leptin, an adipokine with numerous proinflammatory effects, is increased in AD patients [21], while adiponectin, which seems to have an anti-inflammatory role, is found at lower levels in patients with AD [21,22]. Furthermore, obesity has been demonstrated to compromise the epidermal barrier, causing increased transepidermal water loss and skin dryness [23,24].
2. Materials and Methods
2.1. Population
The study population consists of patients with AD under treatment with dupilumab, followed clinically by the Allergological Dermatology Service at the Dermatology Unit of the Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan (Italy). This is a single-center retrospective study. Ethical approval is referred to as protocol Dupi Long Term 2022. All the patients have given written informed consent for the publication of their case details. We collected the data from 170 Caucasian adult patients with severe AD who were treated with dupilumab at standard doses (600 mg at baseline, then 300 mg every other week) for 48 weeks. Patients who did not reach the 48-week follow-up were excluded.
2.2. Data Collection
We collected data on sex, age, height, baseline weight, atopic comorbidities, AD phenotype, atopic family history, AD onset age, the previous use of systemic drugs for AD, and the intake of systemic drugs for AD at baseline. Additionally, the patient’s weight was recorded after 48 weeks of treatment. AD phenotypes were classified according to Salvador et al. [25]. The onset age was further classified as follows: infants (0 years old), children (1–12 years old), adolescents (13–17 years old), and adults (≥18 years old). Patients were divided into two age groups at baseline: 18–49 years old and ≥50 years old. The population was also divided into two groups based on baseline BMI: patients with a BMI < 25 (normal weight) and patients with a BMI ≥ 25 (overweight and obese). For clinical scores, we considered the Eczema Area and Severity Index (EASI) and the following patient-reported outcomes (PROs): Pruritus Numerical Rating Scale (NRS), sleep NRS, Patient-Oriented Eczema Measure (POEM), Dermatology Life Quality Index (DLQI), and Atopic Dermatitis and Control Tool (ADCT). Data were collected at baseline (T0) and after 16 (T16), 32 (T32), and 48 weeks (T48) of treatment.
2.3. Objectives
The aim of the study was to assess a possible correlation between the clinical outcome of dupilumab therapy and baseline BMI. Moreover, we wanted to assess potential weight gain during treatment with dupilumab.
2.4. Statistical Analysis
Statistical analyses were undertaken using SPSS software (IBM, Armonk, NY, USA, version 29.0). Descriptive statistics are reported as mean and standard deviation (SD) or median and 25°–75° quartile (Q1–Q3) for quantitative variables based on the distribution of the population (symmetrical vs. asymmetrical). Absolute numbers (n) and frequencies (%) are used for categorical variables. Dichotomous normal distributions were compared using the Student’s t-test, and dichotomous non-normal distributions were tested using the Mann–Whitney U test. Categorical variables were analyzed using a chi-square test or Fisher’s exact test as appropriate. Paired samples t-tests or Wilcoxon tests were used to investigate potential differences in BMI between T0 and T48, stratifying the population by age and baseline BMI. The improvement of the scores evaluated at different time points was tested using the Wilcoxon test. Pearson’s correlation index was used to assess a potential correlation between the EASI and BMI. We performed a single regression and a multivariate regression analysis to evaluate potential baseline factors influencing an EASI improvement of less than 75% at T48. To calculate the sample size, the power*G software (version 3.1) was used. Considering a t-Student test for two independent samples, with a significance level of 0.05 and 80% power, and assuming an effect size of 0.5 in terms of the EASI score, we determined that a minimum sample size of 72 patients was necessary. All statistical analyses were two-tailed and performed with an alpha error of 0.05. A p-value < 0.05 was considered significant.
3. Results
Our population comprised 170 patients, of which 79 (46.5%) were women and 91 (53.5%) were men. At baseline, the mean age of the population was 40.3 years (SD 16.2). At baseline, 14 (8.2%) patients received systemic corticosteroids (CS), 3 (1.8%) received methotrexate (MTX), and 29 (17.1%) received cyclosporin (CSA). The BMI at T0 ranged from 16.2 to 37.7 with a mean of 23.6. The number of individuals with a BMI < 25 was 118 (69.4%), and individuals with a BMI ≥ 25 consisted of 52 (30.6%) patients. Within the first group, the number of individuals with a BMI < 18.5 was 8 (4.6%), and individuals with a BMI between 18.5 and 24.9 consisted of 110 (64.7%) patients. Within the second group, 43 (25.3%) patients had a BMI between 25.0 and 29.9 (overweight), 7 (4.15%) had a BMI between 30.0 and 34.9 (obesity grade I), and only 2 patients (1.2%) had a BMI over 35.
The baseline epidemiological and clinical characteristics of our overall population, classified by BMI, are summarized in Table 1. There was a significant prevalence of males in the BMI ≥ 25 group compared to the BMI < 25 group (67.3% vs. 47.5%), which reflects the percentage of females (52.5% vs. 32.7%) in the BMI < 25 group. Almost half of the patients had a classical AD phenotype (46.5%), as it is the most common worldwide. The distribution of baseline age showed a slight positive skew, with most patients being young or middle-aged adults; only 22 patients started dupilumab therapy after 60 years of age. There was no statistically significant difference regarding baseline characteristics between the two BMI groups, except for the previous use of MTX (p = 0.034; contingency coefficient [CC] = 0.180), sex (p = 0.017; CC = 0.180), onset age (p = 0.033), and baseline age (p = 0.003).
Table 1.
Baseline clinical and epidemiological characteristics of our overall population (first column) divided into two BMI groups (second and third columns). The last columns indicate if there is a significant or non-significant statistical difference between the two BMI groups. The different apexes indicate the test that was used: # Pearson’s chi-squared; § Fisher’s exact test; CC, contingency coefficient; + independent t-test; and * Mann–Whitney U test. Abbreviations: BMI, body mass index; SD, standard deviation; Q1, 25° quartile; Q3, 75° quartile; AD, atopic dermatitis.
| Baseline Characteristics | Overall Population | BMI < 25 (n = 118) | BMI ≥ 25 (n = 52) | p-Value |
|---|---|---|---|---|
| Baseline age, mean (SD) | 40.3 (16.2) | 37.8 (15.8) | 45.9 (16.0) | 0.003 + |
Sex, n (%)
|
79 (46.5) 91 (53.5) |
62 (52.5) 56 (47.5) |
17 (32.7) 35 (67.3) |
0.017 # (CC = 0.180) |
AD phenotype, n (%)
|
79 (46.5) 5 (2.9) 9 (5.3) 31 (18.2) 27 (15.9) 1 (0.6) 3 (1.8) 15 (8.8) |
55 (46.6) 2 (1.7) 6 (5.1) 25 (21.2) 20 (16.9) 2 (1.7) 2 (1.7) 8 (6.8) |
24 (46.2) 3 (5.8) 3 (5.8) 6 (11.5) 7 (13.5) 1 (1.9) 1 (1.9) 7 (13.5) |
0.264 § |
| Onset age, median (Q1–Q3) | 1.0 (0.0–15.0) | 1.0 (1.0–5.5) | 3.0 (0.0–27.5) | 0.033 * |
Onset age (categories), n (%)
|
71 (41.8) 52 (30.6) 8 (4.7) 39 (22.9) |
54 (45.8) 38 (32.2) 4 (3.4) 22 (18.8) |
17 (32.7) 14 (26.9) 4 (7.7) 17 (32.7) |
0.091 § |
Atopic comorbidities, n (%)
|
123 (72.4) 94 (55.3) 83 (48.8) 28 (16.5) 3 (1.8) 0 (0.0) |
89 (75.4) 70 (59.3) 59 (50.0) 10 (16.1) 2 (1.7) / |
34 (65.4) 24 (46.2) 24 (46.2) 9 (17.3) 1 (1.9) / |
0.177 # 0.112 # 0.644 # 0.485 # 1.00 § / |
| Atopic family history, n (%) | 80 (47.1) | 57 (48.3) | 23 (44.2) | 0.624 # |
Previous systemic treatments, n (%)
|
147 (86.5) 22 (12.9) 8 (4.7) 0 (0.0) |
105 (89.0) 11 (9.3) 5 (4.2) / |
42 (80.8) 11 (21.2) 3 (5.8) / |
0.149 # 0.034 # (CC = 0.180) 0.701 § / |
The number of patients with a BMI < 25 was 118 (69.4%), and those with a BMI ≥ 25 consisted of 52 (30.6%) patients. Since BMI varies among age and sex categories [26], BMI was assessed at T0 and T48, and the population was stratified by age groups and sex [Figure 1]. In the overall population, among patients with a BMI < 25, the mean (SD) BMI was 21.4 (2.0) at T0 and 21.6 (2.1) at T48, while among patients with a BMI ≥ 25, the mean (SD) BMI was 28.4 (2.7) at T0 and 28.8 (4.6) at T48. No significant differences were found in BMI between T0 and T48 among any age, sex, or baseline BMI groups.
Figure 1.
Mean BMI (at T0 and T48) stratified by age, sex, and baseline BMI groups. Patients were classified into two age groups: between 18 and 49 years old and ≥50 years old. Abbreviations: y/o, years old; BMI, body mass index; T, time point in weeks.
Regarding the EASI score, in patients with a BMI < 25, the median (Q1–Q3) EASI at T0 was 26.0 (24.0–30.0), 6.0 (3.0–10.0) at T4, 3.0 (1.0–6.0) at T16, 2.0 (1.0–4.0) at T32, and 2.0 (1.0–4.0) at T48. Among patients with a BMI ≥ 25, the median (Q1–Q3) EASI at T0 was 26.0 (24.0–30.8), 7.0 (2.0–12.0) at T4, 4.0 (2.0–7.8) at T16, 3.0 (1.0–5.0) at T32, and 2.0 (1.0–5.0) at T48. In patients with a BMI < 25, the median (Q1–Q3) EASI percentage improvement was 79.2 (62.0–88.1) at T4, 88.2 (76.7–96.0) at T16, 92.0 (87.5–96.7) at T32, and 94.3 (87.5–97.5) at T48. Among patients with a BMI ≥ 25, the median (Q1–Q3) EASI percentage improvement was 75.5 (65.2–85.4) at T4, 86.6 (77.0–93.2) at T16, 89.3 (82.4–95.8) at T32, and 92.4 (81.4–96.9) at T48 [Figure 2]. The EASI score was significantly improved as early as the first 4-week follow-up [Supplementary Materials—Table S1]. No significant difference was found at baseline between the two BMI groups. Although the difference in the absolute EASI score and its percentage improvement between the two BMI groups is not statistically significant at any time point [Supplementary Materials—Table S2], it is inferred that the improvement in the EASI is slower in patients with a BMI ≥ 25. However, this difference is not clinically significant. No statistically significant correlation was found between BMI at T0 and the EASI at T0, or between BMI at T48 and the EASI at T48.
Figure 2.
EASI percentage improvement (represented by median) trend stratified by BMI groups (BMI < 25 and BMI ≥ 25). Abbreviations: EASI, Eczema Area and Severity Score Index; BMI, body mass index; T, time point in weeks.
The percentage of patients achieving at least 90% improvement in the EASI (EASI-90) at T48 is 42.4% in the BMI < 25 group vs. 36.5% in the BMI ≥ 25 group. The percentage of patients reaching EASI-100 is similar in both groups (22.9% vs. 23.1%). The percentage of patients with a BMI ≥ 25 not reaching EASI-75 is higher (13.5% vs. 5.9%) compared to patients with an EASI < 25, but the difference is not statistically significant [Figure 3]. Despite this, according to single and multivariate regression analyses, no factor among phenotype, BMI, sex, atopic family history, onset age, the number of atopic comorbidities, or the intake of systemic drugs at baseline appeared to increase the risk of not reaching EASI-75 at T48 [Supplementary Materials—Table S3].
Figure 3.
Distribution of population (%) based on EASI improvement after 48 weeks of treatment: improvement inferior to 75% from baseline (<EASI-75), improvement of at least 75% (EASI-75), EASI-90, and EASI-100. Patients are classified by BMI group (BMI < 25 and BMI ≥ 25). Abbreviations: BMI, body mass index; EASI, Eczema Area and Severity Index.
The trends of pruritus/sleep NRS, ADCT, POEM, and DLQI by BMI group at different time points are reported in Table 2 and in greater detail in the Supplementary Materials [Tables S1 and S2]. Ten patients were excluded from the ADCT analysis due to missing data at T48. All the scores evaluated were significantly improved as early as the first 4-week follow-up [Supplementary Materials—Table S1]. No statistically significant differences were found between the two BMI groups at T0 for pruritus NRS, sleep NRS, and POEM. A statistically significant difference was found at baseline for ADCT (p = 0.043) since the median ADCT score in the normal BMI group was slightly lower (21.5 vs. 20.0). A statistically significant difference in DLQI percentage improvement was found at T4 (p = 0.022) and T16 (p = 0.002), indicating that normal-weight patients had better median DLQI improvement at T4 (73.7 vs. 59.0), whereas overweight and obese patients had better improvement at T16 (89.2 vs. 73.6). Additionally, a statistically significant difference was found for POEM at T16 (p = 0.013), with overweight and obese patients showing greater score improvement [Supplementary Materials—Table S2].
Table 2.
An assessment of pruritus NRS, sleep NRS, POEM, ADCT, and DLQI, compared between the two BMI groups at different time points. The percentage improvement is represented as a median (Q1–Q3). Abbreviations: BMI, body mass index; POEM, Patient-Oriented Eczema Measure; DLQI, Dermatology Life Quality Index; ADCT, Atopic Dermatitis Control Tool; NRS, Numerical Rates Scale; T, time point in weeks.
| Score | BMI Group | T0 | Improvement (%) T0–T4 | Improvement (%) T0–T16 | Improvement (%) T0–T32 | Improvement (%) T0–T48 |
|---|---|---|---|---|---|---|
| Pruritus NRS (n = 170) |
BMI < 25 | 9.0 (8.0–10.0) | 60.0 (39.4–77.8) | 70.0 (37.5–87.5) | 70.0 (52.8–88.9) | 70.0 (50.0–90.0) |
| BMI ≥ 25 | 9.0 (8.0–10.0) | 53.6 (30.0–77.8) | 70.7 (55.6–87.5) | 75.0 (41.1–90.0) | 75.0 (34.4–90.0) | |
| Sleep NRS (n = 170) |
BMI < 25 | 8.0 (6.0–10.0) | 88.9 (53.6–100.00) | 100.0 (64.6–100.0) | 100.0 (83.9–100.0) | 100.0 (100.0–100.0) |
| BMI ≥ 25 | 7.0 (4.3–9.0) | 85.7 (50.0–100.0) | 100.0 (71.4–100.0) | 100.0 (77.8–100.0) | 100.0 (71.0–100.0) | |
| POEM (n = 170) |
BMI < 25 | 23.0 (18.0–26.0) | 61.1 (30.8–79.6) | 63.6 (38.8–81.6) | 75.0 (55.6–86.4) | 72.1 (50.0–84.9) |
| BMI ≥ 25 | 23.5 (20.0–28.0) | 60.7 (41.3–81.9) | 78.8 (54.7–86.6) | 71.4 (44.2–90.7) | 76.3 (58.2–89.3) | |
| ADCT (n = 160) |
BMI < 25 | 20.0 (16.8–23.0) | 64.9 (50.7–75.0) | 73.9 (60.0–83.3) | 81.3 (70.0–92.3) | 81.8 (71.4–92.3) |
| BMI ≥ 25 | 21.5 (18.0–24.0) | 62.5 (47.8–72.7) | 71.4 (55.6–80.0) | 77.3 (63.6–91.7) | 76.5 (63.2–91.3) | |
| DLQI (n = 170) |
BMI < 25 | 15.0 (11.0–20.25) | 73.7 (42.7–90.2) | 73.6 (45.3–88.9) | 83.3 (61.7–92.8) | 83.3 (62.4–93.3) |
| BMI ≥ 25 | 14.0 (10.0–20.0) | 59.0 (28.0–79.9) | 89.2 (71.2–95.0) | 80.0 (50.0–93.1) | (74.0–96.1) |
4. Discussion
We investigated a potential difference regarding the baseline characteristics among the two BMI groups. A statistically significant difference was found for the previous use of MTX, sex, onset age, and baseline age. The difference concerning sex was due to the higher number of males in the BMI ≥ 25 group. However, there are no data in the literature regarding a different response to dupilumab between males and females. Moreover, the contingency coefficient was very close to 0 (0.180), indicating a weak association. The statistically significant difference in previous MTX intake was due to 21.2% of patients in the BMI ≥ 25 group having been treated with MTX, compared to 9.3% in the BMI < 25 group. However, the previous use does not indicate that the patients were on MTX when starting dupilumab, so there is no interference with the clinical response to dupilumab. The difference in onset age is statistically significant but not clinically significant, with medians of 1.0 vs. 3.0 years for the BMI < 25 and BMI ≥ 25 groups, respectively. When considering onset age categorically (infants, children, adolescents, and adults), the difference is not statistically significant. The statistically significant difference in baseline age reflects a gap of over 10 years between the means of the two BMI groups, due to selection bias, and there is no evidence that overweight or obese patients access biologic therapy later. No different response to dupilumab in different age groups has been demonstrated [27].
Regarding our study, no differences were found in BMI between T0 and T48 among any age, sex, or baseline BMI group, meaning that dupilumab treatment does not seem to impact weight. To our knowledge, only one report has described a possible association between weight gain and treatment with dupilumab. In a Swedish study involving 12 AD patients treated with dupilumab, all patients experienced significant weight gain (mean: 6.1 kg) after 48 weeks of follow-up [16]. However, there was no significant correlation between weight gain and treatment response, reported appetite, or sleep disturbances caused by itching. Nonetheless, a study conducted on a population of only 12 subjects has limited significance. Additionally, the dupilumab randomized phase 3 studies (SOLO 1, SOLO 2, AD ADOL, and CHRONOS) did not evaluate potential weight gain during treatment [28], and no other studies have mentioned it [29]. In contrast, our study was conducted on a statistically significant and better representative sample of the AD population.
Jung MJ et al. demonstrated how weight reduction impacts the improvement of AD symptoms. Forty subjects with AD were divided into a weight maintenance group and a weight reduction group. In the weight reduction group, there was a significant improvement in the Eczema Area and Severity Index (EASI) score (BMI and the EASI showed a positive correlation), while no significant improvement was observed in the weight maintenance group [20]. In the field of psoriasis, it has already been known for several years that weight and BMI have an impact on the clinical response to biologics, namely that optimal responses to fixed-dose biological agents are less common in patients with increasing weight [30]. BMI influences the initial clinical response to systemic treatment for psoriasis [31], and reducing body weight in obese patients receiving biologics may enhance the drug’s efficacy [32]. With regard to our study, patients with a BMI < 25 have a higher EASI percentage improvement [Figure 2], which ranges from 1.9 to 3.7 points of difference. This suggests a trend where overweight and obese patients may take longer to fully respond to dupilumab treatment. However, this numerical difference does not appear to be clinically significant, meaning it may not impact treatment decisions in practice. Our results are in line with those of Patruno et al. [33], who showed that BMI correlates with a lower effectiveness of dupilumab during the first weeks of therapy. Even if not statistically significant, the percentage of overweight and obese patients who do not reach EASI-75 is higher compared to normal-weight patients (13.5% vs. 5.9%). Despite this, the multivariate analysis found that no baseline factor, including BMI, appeared to increase the risk of not reaching EASI-75 at T48. This underscores the complexity of factors influencing treatment response in AD beyond BMI alone, including genetic predispositions, disease severity, and other clinical variables. Overall, while BMI may influence the rate of improvement in AD symptoms with dupilumab therapy, its impact appears nuanced and not a decisive factor in predicting treatment outcomes based on our findings, especially when considering other variables in the analysis.
When considering PROs, patients with a BMI < 25 showed a better DLQI improvement at T4 (even though the result is the opposite at T16) and a better POEM improvement at T16. The percentage improvement is not statistically significantly different at T48 between the two BMI groups. These findings suggest that BMI may influence certain aspects of treatment efficacy in the first weeks of treatment.
Limitations
The limitations mainly relate to the retrospective nature of the study. In addition, patients’ weight was reported by patients using personal scales at home. Subanalyses could not be conducted within the group of patients with BMI ≥ 25 because the obese category was underrepresented numerically (n = 9). Our study showed some difference in the percentage improvement of the EASI that should be confirmed in a larger case series, where the subpopulations of underweight, overweight, and obese patients are better represented. Based on the sample size analysis, our sample is adequate. However future research is warranted to validate and strengthen the robustness and reliability of the findings.
5. Conclusions
No differences were found in BMI between T0 and T48 among any age, sex, or baseline BMI group, meaning that dupilumab treatment does not seem to impact weight. Even if not significant, patients with a BMI < 25 have a higher EASI percentage improvement, suggesting a trend where overweight and obese patients may take longer to fully respond to dupilumab treatment. However, this numerical difference does not appear to be clinically significant, meaning it may not impact treatment decisions in practice.
Supplementary Materials
The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/jcm13154559/s1. Table S1: An assessment of the EASI, pruritus NRS, sleep NRS, POEM, ADCT, and DLQI, stratified by BMI group, at different time points. Table S2: An assessment of the percentage improvement of the EASI, pruritus NRS, sleep NRS, POEM, ADCT, and DLQI, compared between the two BMI groups, at different time points. Table S3: Single and multivariate regression analyses evaluating a potential predominating factor for the determination of an EASI improvement inferior to 75% (EASI-75) at T48.
Author Contributions
Conceptualization, S.N. and F.B.; methodology, S.N. and F.B.; software, S.F.; validation, S.F.; formal analysis, S.N., F.B. and S.F.; investigation, F.B. and S.M.F.; data curation, S.N. and F.B.; writing—original draft, S.N. and F.B.; writing—review and editing, S.N., F.B., M.R., A.V.M. and S.M.F.; supervision, A.V.M. and S.M.F.; project administration, S.M.F.; funding acquisition, A.V.M. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
This study was approved by the Ethics Committee of Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico of Milan (Dupi Long Term 20221157_2022; 22 December 2022).
Informed Consent Statement
The patients in this manuscript have given written informed consent to the publication of their case details.
Data Availability Statement
Data are not available due to privacy restrictions.
Conflicts of Interest
S. Ferrucci is the principal investigator in a clinical trial of Amgen, Sanofi, Novartis, Lilly, Leo Pharma, and Abbvie, and she is an advisory board speaker for Novartis, Menarini, Sanofi, Abbvie, and Leo Pharma. F. Barei has a conflict of interest with Leo Pharma and Almirall. The other authors declare that there are no conflicts of interest. A.V.M. is on the advisory board and receives disease-relevant honoraria from Abbvie, Boheringer-Ingelheim, Novartis, Pfizer, Sanofi and UCB.
Funding Statement
This research received no external funding.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.Maintz L., Schmitz M.T., Herrmann N., Müller S., Havenith R., Brauer J., Rhyner C., Dreher A., Bersuch E., Fehr D., et al. Atopic dermatitis: Correlation of distinct risk factors with age of onset in adulthood compared to childhood. Allergy. 2023;78:2181–2201. doi: 10.1111/all.15721. [DOI] [PubMed] [Google Scholar]
- 2.Weidinger S., Beck L.A., Bieber T., Kabashima K., Irvine A.D. Atopic dermatitis. Nat. Rev. Dis. Primers. 2018;4:1. doi: 10.1038/s41572-018-0001-z. [DOI] [PubMed] [Google Scholar]
- 3.Sroka-Tomaszewska J., Trzeciak M. Molecular Mechanisms of Atopic Dermatitis Pathogenesis. Int. J. Mol. Sci. 2021;22:4130. doi: 10.3390/ijms22084130. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Napolitano M., Fabbrocini G., Martora F., Genco L., Noto M., Patruno C. Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication. Dermatol. Ther. 2022;35:e15901. doi: 10.1111/dth.15901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Abuabara K., Yu A.M., Okhovat J.P., Allen I.E., Langan S.M. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy. 2018;73:696–704. doi: 10.1111/all.13320. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Bylund S., Kobyletzki L.B., Svalstedt M., Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm. Venereol. 2020;100:adv00160. doi: 10.2340/00015555-3510. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A., Gieler U., Girolomoni G., Lau S., Muraro A., et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. J. Eur. Acad. Dermatol. Venereol. 2018;32:657–682. doi: 10.1111/jdv.14891. Erratum in J. Eur. Acad. Dermatol. Venereol. 2019, 33, 1436. [DOI] [PubMed] [Google Scholar]
- 8.Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A., Gieler U., Girolomoni G., Lau S., Muraro A., et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II. J. Eur. Acad. Dermatol. Venereol. 2018;32:850–878. doi: 10.1111/jdv.14888. [DOI] [PubMed] [Google Scholar]
- 9.Kimball A.B., Delevry D., Yang M., Chuang C.C., Wang Z., Bégo-Le-Bagousse G., Martins B., Wu E., Shumel B., Wang J., et al. Long-Term Effectiveness of Dupilumab in Patients with Atopic Dermatitis: Results up to 3 Years from the RELIEVE-AD Study. Dermatol. Ther. 2023;13:2107–2120. doi: 10.1007/s13555-023-00965-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Beck L.A., Deleuran M., Bissonnette R., de Bruin-Weller M., Galus R., Nakahara T., Seo S.J., Khokhar F.A., Vakil J., Xiao J., et al. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am. J. Clin. Dermatol. 2022;23:393–408. doi: 10.1007/s40257-022-00685-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Beck L.A., Thaçi D., Deleuran M., Blauvelt A., Bissonnette R., de Bruin-Weller M., Hide M., Sher L., Hussain I., Chen Z., et al. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Am. J. Clin. Dermatol. 2020;21:567–577. doi: 10.1007/s40257-020-00527-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ortoncelli M., Macagno N., Mastorino L., Gelato F., Richiardi I., Cavaliere G., Quaglino P., Ribero S. Long-Term Efficacy and Safety of Dupilumab in Patients with Atopic Dermatitis: A Single-Centre Retrospective Study. Cosmetics. 2023;10:153. doi: 10.3390/cosmetics10060153. [DOI] [Google Scholar]
- 13.Barei F., Zussino M., Tavecchio S., Angileri L., Rizzo A., Calzari P., Marzano A.V., Ferrucci S. Assessment of Patient-Reported Outcomes at 48 Months of Treatment with Dupilumab for Severe Atopic Dermatitis: A Single-Center Real-Life Experience with 126 Patients. Pharmaceuticals. 2024;17:117. doi: 10.3390/ph17010117. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Perego G., Aromolo I.F., Barei F., Valtellini L., Marzano A.V., Ferrucci S. Effectiveness of dupilumab in atopic dermatitis on the head and neck: A single-center study on 553 patients. Int J Dermatol. 2024;63:e178–e179. doi: 10.1111/ijd.17278. [DOI] [PubMed] [Google Scholar]
- 15.Ferrucci S., Tavecchio S., Maronese C.A., Balato A., Di Brizzi E., Ortoncelli M., Ribero S., Girolomoni G., Maurelli M., Belloni Fortina A., et al. Short-, mid- and long-term efficacy of dupilumab in moderate to severe atopic dermatitis: A real life multicenter Italian study on 2576 patients. Clin. Exp. Dermatol. 2024:llae208. doi: 10.1093/ced/llae208. [DOI] [PubMed] [Google Scholar]
- 16.Spekhorst L.S., de Graaf M., Zuithoff N.P.A., van den Reek J.M.P.A., Kamsteeg M., Boesjes C.M., Romeijn G.L.E., Loman L., Haeck I., Oosting A.J., et al. Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry. JAMA Dermatol. 2022;158:1048–1056. doi: 10.1001/jamadermatol.2022.3014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Johansson E.K., Ivert L.U., Bradley B., Lundqvist M., Bradley M. Weight gain in patients with severe atopic dermatitis treated with dupilumab: A cohort study. BMC Dermatol. 2020;20:8. doi: 10.1186/s12895-020-00103-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Zhang A., Silverberg J.I. Association of atopic dermatitis with being overweight and obese: A systematic review and metaanalysis. J. Am. Acad. Dermatol. 2015;72:606–616.e4. doi: 10.1016/j.jaad.2014.12.013. [DOI] [PubMed] [Google Scholar]
- 19.Ali Z., Suppli Ulrik C., Agner T., Thomsen S.F. Is atopic dermatitis associated with obesity? A systematic review of observational studies. J. Eur. Acad. Dermatol. Venereol. 2018;32:1246–1255. doi: 10.1111/jdv.14879. [DOI] [PubMed] [Google Scholar]
- 20.Jung M.J., Kim H.R., Kang S.Y., Kim H.O., Chung B.Y., Park C.W. Effect of Weight Reduction on Treatment Outcomes for Patients with Atopic Dermatitis. Ann. Dermatol. 2020;32:319–326. doi: 10.5021/ad.2020.32.4.319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Jaworek A.K., Szepietowski J.C., Szafraniec K., Jaworek M., Hałubiec P., Wojas-Pelc A., Pokorski M. Adipokines as Biomarkers of Atopic Dermatitis in Adults. J. Clin. Med. 2020;9:2858. doi: 10.3390/jcm9092858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Nagel G., Koenig W., Rapp K., Wabitsch M., Zoellner I., Weiland S.K. Associations of adipokines with asthma, rhinoconjunctivitis, and eczema in German schoolchildren. Pediatr. Allergy Immunol. 2009;20:81–88. doi: 10.1111/j.1399-3038.2008.00740.x. [DOI] [PubMed] [Google Scholar]
- 23.Loffler H., Aramaki J.U., Effendy I. The influence of body mass index on skin susceptibility to sodium lauryl sulphate. Skin Res. Technol. 2002;8:19–22. doi: 10.1046/j.0909-752x. [DOI] [PubMed] [Google Scholar]
- 24.Nino M., Franzese A., Ruggiero Perrino N., Balato N. The effect of obesity on skin disease and epidermal permeability barrier status in children. Pediatr. Dermatol. 2012;29:567–570. doi: 10.1111/j.1525-1470.2012.01738.x. [DOI] [PubMed] [Google Scholar]
- 25.Silvestre Salvador J.F., Romero-Pérez D., Encabo-Durán B. Atopic Dermatitis in Adults: A Diagnostic Challenge. J. Investig. Allergol. Clin. Immunol. 2017;27:78–88. doi: 10.18176/jiaci.0138. [DOI] [PubMed] [Google Scholar]
- 26.Jabre J.F., Bland J.D.P. Body mass index changes: An assessment of the effects of age and gender using the e-norms method. BMC Med. Res. Methodol. 2021;21:40. doi: 10.1186/s12874-021-01222-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Silverberg J.I., Lynde C.W., Abuabara K., Patruno C., de Benedetto A., Zhang H., Thomas R.B., Bégo-Le-Bagousse G., Khokhar F.A., Vakil J., et al. Efficacy and Safety of Dupilumab Maintained in Adults ≥ 60 Years of Age with Moderate-to-Severe Atopic Dermatitis: Analysis of Pooled Data from Four Randomized Clinical Trials. Am. J. Clin. Dermatol. 2023;24:469–483. doi: 10.1007/s40257-022-00754-4. Erratum in Am. J. Clin. Dermatol. 2023, 24, 673. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Silverberg J.I., Yosipovitch G., Simpson E.L., Kim B.S., Wu J.J., Eckert L., Guillemin I., Chen Z., Ardeleanu M., Bansal A., et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J. Am. Acad. Dermatol. 2020;82:1328–1336. doi: 10.1016/j.jaad.2020.02.060. [DOI] [PubMed] [Google Scholar]
- 29.Halling A.S., Loft N., Silverberg J.I., Guttman-Yassky E., Thyssen J.P. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2021;84:139–147. doi: 10.1016/j.jaad.2020.08.051. [DOI] [PubMed] [Google Scholar]
- 30.Puig L. Obesity and psoriasis: Body weight and body mass index influence the response to biological treatment. J. Eur. Acad. Dermatol. Venereol. 2011;25:1007–1011. doi: 10.1111/j.1468-3083.2011.04065.x. [DOI] [PubMed] [Google Scholar]
- 31.Naldi L., Addis A., Chimenti S., Giannetti A., Picardo M., Tomino C., Maccarone M., Chatenoud L., Bertuccio P., Caggese E., et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology. 2008;217:365–373. doi: 10.1159/000156599. [DOI] [PubMed] [Google Scholar]
- 32.Al-Mutairi N., Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: A randomized controlled prospective trial. Expert Opin. Biol. Ther. 2014;14:749–756. doi: 10.1517/14712598.2014.900541. [DOI] [PubMed] [Google Scholar]
- 33.Patruno C., Potestio L., Cecere D., Cosenza A., Brescia C., Napolitano M. The impact of body mass index on dupilumab treatment outcomes in adult atopic dermatitis patients. J. Eur. Acad. Dermatol. Venereol. 2024 doi: 10.1111/jdv.20111. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data are not available due to privacy restrictions.